Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Epstein-Barr Virus
New Epstein-Barr virus study results from Y. Chen et al described
January 21st, 2009
"Epstein-Barr virus (EBV), a potential oncogenic herpesvirus, has been found to be associated with several malignancies. It's critical to elicit cellular immunity of the body to fight against EBV-associated tumor development," researchers in Nanjing, People's Republic of China report. "Using dendritic cells (DCs) loaded with latent membrane protein 2A (LMP2A) to elicit T cell response against tumor may be one of the most direct and safest immunotherapy approaches. The present study aimed to develop DCs-based cancer vaccine (DC loaded with LMP2A protein) and study its biological characteristics and immune functions. Purified LMP2A protein was extracted from a cell line...
Source: Vaccine Weekly (2009-01-21)
|
